Press releases
- Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
- Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
- Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
- Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
- Veracyte Completes Acquisition of C2i Genomics
- Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
More ▼
Key statistics
As of last trade Veracyte Inc (12V:BER) traded at 19.90, 7.57% above its 52-week low of 18.50, set on Oct 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 19.90 |
---|---|
High | 19.90 |
Low | 19.90 |
Bid | 20.20 |
Offer | 20.40 |
Previous close | 19.40 |
Average volume | 1.67 |
---|---|
Shares outstanding | 78.44m |
Free float | 77.53m |
P/E (TTM) | -- |
Market cap | 1.70bn USD |
EPS (TTM) | -1.02 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 07:06 BST.
More ▼